一图解码：麦科田赴港IPO 专注医疗器械行业 上半年业绩扭亏

Core Viewpoint - The company, Medcaptain, has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, aiming to raise funds for research and development, manufacturing expansion, and strategic investments to enhance its competitive product portfolio [3][4]. Company Overview - Medcaptain is a global provider of medical solutions, offering a comprehensive range of innovative products that cater to various clinical needs across hospitals, clinics, and home care settings [4][5]. - As of June 30, 2025, Medcaptain has commercialized over 340 products, including more than 50 life support products, 80 minimally invasive intervention products, and 210 in vitro diagnostic products [6][8]. Market Presence - Medcaptain's products are available in over 140 countries and regions, with a significant presence in China, covering more than 6,000 hospitals, including approximately 90% of top-tier hospitals [10][12]. - The company has established a strong global sales and marketing platform, focusing on high-quality innovative medical products to meet unmet clinical needs [9]. Financial Performance - For the six months ending June 30, 2025, Medcaptain reported revenue of approximately 787 million RMB, representing a year-on-year growth of about 15.3%. The company achieved a profit attributable to shareholders of approximately 40.19 million RMB, compared to a loss of about 57.77 million RMB in the same period the previous year [12][13]. Fundraising Purpose - The net proceeds from the IPO are intended for various purposes, including ongoing and planned R&D to enrich the product line, expanding manufacturing capabilities, enhancing sales and marketing efforts, and funding potential strategic investments and acquisitions [4][5].